Preclinical Pharmacokinetics and Translational Pharmacokinetic/Pharmacodynamic Modeling of M8891, a Potent and Reversible Inhibitor of Methionine Aminopeptidase 2.

Floriane LignetManja Friese-HamimFrank JaehrlingSamer El BawabFelix Rohdich

Published in: Pharmaceutical research (2023)

The defined target PK and PD levels supported the design of the clinical Phase Ia dose escalation study of M8891 (NCT03138538) and selection of the recommended Phase II dose.

Keyphrases

phase ii
open label
clinical trial
phase iii
stem cells
cell therapy
double blind
amino acid
mesenchymal stem cells
bone marrow